Company intelligence / Profile preview

Dymicron

Ownership: Private
Development stage: Commercial

Overview

Dymicron’s flagship product, Triadyme-C, is a next-generation cervical total disc replacement made from Adymite polycrystalline diamond. It has CE Mark approval and is commercially available in select European and South American markets. Over 1,000 devices have been implanted with good patient outcomes. The company is pursuing FDA Premarket Approval for US commercialization. Clinical results indicate excellent durability, biocompatibility, minimal wear debris generation, and natural motion preservation.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy (orthopedic implants)
Industry: Implantable Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Dymicron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dymicron.

Explore the full profile